LEF1 and cancer: The LEF1-targeting O’PROTAC (LEF1 OP-V1) and the ERG-targeting O’PROTAC (ERG OP-C-N1) both employed a VHL E3 ligase ligand, effectively inducing target protein degradation in nanomolar concentrations in the tens and subsequently inhibiting cancer cell growth both in vitro and in vivo [61].